Business Wire

CA-DENODO

2.9.2020 09:02:09 CEST | Business Wire | Press release

Share
Adoption of Denodo Coronavirus Data Portal Initiative Grows as More Customers and Partners Use It to Fight and Minimize the Impact of COVID-19

Denodo , the leader in data virtualization, today announced increased adoption of its Coronavirus Data Portal (CDP), an open, cooperative effort that utilizes data virtualization to unify critical datasets originally exposed in different formats from multiple sources and countries. Originally developed in March during early onset of the pandemic, Denodo has combined and unified COVID-19 related intelligence and made it available to data consumers such as data scientists, analysts, and researchers who are leveraging the information to find solutions to this global disease. For more information, and to participate in the effort, visit https://www.coronavirusdataportal.com .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200902005272/en/

“In an effort to measure and monitor the health of our employees, we needed to create a way for them to tell us about their own health and to provide the clinical teams and leadership with details on who is healthy and who is not before coming to work,” said Mahendra Parasmal, Sr. Information Architect at Spectrum Health . “Denodo provides us with the ability to connect self-purported health data provided by employees via an online survey with employee demographics, employee hierarchy, badge system & Active Directory data virtually. This delivers wellness information in near real-time without having to Extract, Transform & Load the data physically from source systems or run batch incremental loads. As a result, we have been able to speed up our overall build time by at least 3x and deliver the end result in weeks instead of months.”

Free of charge to participants, the Coronavirus Data Portal enables organizations and institutions to share their individual data sets that Denodo integrates and offers to the broader community for consumption via the data platform. It also allows members to integrate and curate these data sets so they can augment their own COVID-19 initiatives. As of today, there are 64 sources, 220 datasets, and 441 views offered on CDP.

“I can personally attest to how our company was able to leverage Denodo’s Coronavirus Data Portal having developed a COVID-19 virtual hub that provides reports based on data science and pmOne Share ,” said Dr. Norman Bernhardt, Head of Digital Solutions R&D, pmOne . “pmOne Share Cockpit aggregates existing and established reporting solutions and provides advanced filtering capabilities, which data scientists can use to develop algorithms to analyze global news flows, the results of which are displayed in a dashboard.”

More specifically, Denodo’s CDP is being used to:

  • Search the Curated Datasets: Coronavirus Data Portal offers a catalog of the curated data sets - both uploaded and curated by Denodo data stewards and those contributed by users of the data portal. This allows users to search the available data sets and find the data relevant to them such as details about the spread of the disease, school closures, financial impact, etc. It also enables them to drill deeper to view details about a particular data set and its relationship with other ones.
  • Enhance Dashboard BI Tools with Integrated Data Portal: CDP supports BI tools such as Power BI, Tableau and others so participants can connect to the data portal and generate smart visualizations. Users can use these tools to easily create new customized reports of the integrated data.
  • Extend Data integration Using API Service/Downloadable CSV Datasets: Lets users further integrate their application with the Coronavirus Data Platform, utilizing it as an API service layer. This enables users to access the curated data sets in a variety of views and is an option that is growing significantly as more and more multi-faceted data is added from across the globe.
  • Contribute to the Initiative: The Coronavirus Data Portal is an open platform, which permits users to contribute their own data sets to the initiative. It suggests data sources that should be added to the Data Portal and Denodo’s data steward team will review the data and usage permissions to determine if it’s appropriate to be uploaded. Alternatively, they can create new data sets by combining the Coronavirus Data Portal data with their own data and share this new data set with other Data Portal users.

“While our data stewards and data engineers have been working behind the scenes to add more data sets to the Coronavirus Data Portal, we have also been getting some great suggestions from the user community. Based on suggestions, we’ve added COVID-19 forecast data, real-time information about how many are infected and where, school closures, global news as they are published, and much more,” said Angel Viña, CEO and Founder at Denodo. “Contributing data sets - either through suggestions or by creating derived data sets - will continue the growth of the Coronavirus Data Portal and enhance the value that fellow users are getting from using the data. This continued growth will provide more varied and richer data for all of us to use and share in our efforts to combat this deadly pandemic.”

Please Tweet: News: #datavirtulization provider @denodo offers complimentary #coronavirus data portal to unify #datasets and information to fight #COVID19

About Denodo

Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release

Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye